Nanoscintillator-based X-ray sensitizers to enable efficient NSCLC treatment with X-ray irradiation
基于纳米闪烁体的 X 射线敏化剂可通过 X 射线照射实现有效的 NSCLC 治疗
基本信息
- 批准号:9311376
- 负责人:
- 金额:$ 49.23万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2017
- 资助国家:美国
- 起止时间:2017-03-15 至 2021-01-31
- 项目状态:已结题
- 来源:
- 关键词:AdoptedAdverse effectsAnimalsAreaAttentionBiodistributionBiological AssayBody SizeBody partCancer EtiologyCellsCetuximabCharacteristicsClinicClinicalClinical OncologyComplementDNADNA DamageDevelopmentDiagnosisDiseaseDoseElementsEnergy-Generating ResourcesEsophagitisExternal Beam Radiation TherapyFluorescent DyesFormulationGoalsHead and Neck CancerHistologyIn VitroIndividualInjectableLabelLeadLigandsLightLipid PeroxidationLipid PeroxidesLow Dose RadiationMainstreamingMalignant NeoplasmsMalignant neoplasm of lungMalignant neoplasm of prostateMarriageMaximum Tolerated DoseMembrane LipidsMethodologyModalityModelingMonitorMusNanostructuresNanotechnologyNeutropenic FeverNon-Small-Cell Lung CarcinomaNormal tissue morphologyPUVA PhotochemotherapyPatientsPenetrationPersonsPharmaceutical PreparationsPhotonsPhotosensitizationPhotosensitizing AgentsPositron-Emission TomographyProductionProtocols documentationRadiationRadiation therapyRadioisotopesRattusRefractoryResearchResistanceRoentgen RaysSeriesSilicon DioxideSinglet OxygenSkinSurfaceSystemTechnologyTherapeutic procedureThickTimeTissuesToxic effectTransducersTreatment EfficacyTreatment ProtocolsTreatment outcomeVisible Radiationbasecancer cellcancer invasivenesscancer therapycancer typecell killingchemotherapyclinical translationconventional therapycytotoxicimage guidedinterestirradiationkillingsluminescencemalignant breast neoplasmminimally invasivemortalitynanoparticlenanosystemsnew technologynovelnovel therapeuticspre-clinicalradioresistantrepairedresponsestandard of carestemsuccesstherapy outcometumoruptakevirtual
项目摘要
Abstract
Photodynamic therapy (PDT) has gained much attention as a relatively new cancer treatment modality. PDT
has a favorable toxicity profile compared to radiotherapy. Meanwhile, it does not incur resistance, and can be
applied to previously irradiated tissues. However, the use of PDT in the clinic has been very limited. This is
largely due to its surface-weighted treatment efficacy, a result of limited penetration depth of light in tissues.
Our long term objective is to develop a novel PDT derivative called X-ray induced PDT or X-PDT that can
break the shallow penetration limitation. Our strategy is to use X-ray, which has great tissue penetration ability,
as the energy source to trigger PDT. The key element of our technology is an integrated nanosystem, consisting
of a scintillator nanoparticle core and photosensitizing drugs that match the scintillator’s emission wavelength.
Upon X-ray irradiation, the nanoparticle scintillator functions as a transducer, converting X-ray photons to visible
light photons. The visible photons, in turn, activate the near-by photosensitizing drugs to produce a cytotoxic
species called singlet oxygen. Owing to the excellent transmittance of X-ray, X-PDT can be activated from deep
tissues. Moreover, it was found that X-PDT is essentially a combination of PDT and radiotherapy. This leads to
synergistic treatment outcomes, allowing X-PDT to efficiently kill cancer cells at low radiation doses, even for
cancer cells that are refractory to radiotherapy. These characteristics make X-PDT an appealing treatment
methodology.
The present project will exploit X-PDT to treat non–small cell lung cancer (NSCLC), which is challenging or
not possible for conventional PDT. NSCLC accounts for 85% of all lung cancer cases, and is diagnosed in
187,000 persons each year. Radiation, often concurrent with chemotherapy, is the standard of care for the
majority of the patients. The treatment, however, may cause severe side effects such as neutropenic fever and
Grade 3 esophagitis. Once recur, treatment options are limited since the radiation has been given to the
maximum tolerated dose. Hence, there is an urgent need for an effective and less toxic treatment for NSCLC. It
is expected that X-PDT can efficiently kill NSCLC through external radiation of relatively low doses with minimal
collateral damage.
Success of this project will be paradigm-shifting, breaking the shallow penetration dogma of conventional
PDT and opening many new possibilities. X-PDT holds great potential in clinical translation, complementing or
replacing current treatment regimens for NSCLC therapy. Although the current study is focused on NSCLC, the
methodology can be easily extended to treatment of other cancer types, for instance head and neck cancer,
breast cancer, and prostate cancer.
摘要
光动力疗法(PDT)作为一种相对较新的肿瘤治疗方法已引起人们的广泛关注。光动力疗法
与放射治疗相比,具有更好的毒性特征。同时,它不会招致阻力,而且可以
适用于先前受过辐射的组织。然而,光动力疗法在临床上的应用一直非常有限。这是
这在很大程度上是由于其表面加权的治疗效果,这是光在组织中的穿透深度有限的结果。
我们的长期目标是开发一种新的PDT衍生物,称为X射线诱导PDT或X-PDT,它可以
打破浅层侵彻限制。我们的策略是使用X射线,它具有很强的组织穿透能力,
作为触发光动力疗法的能源。我们技术的关键要素是一个集成的纳米系统,包括
闪烁体纳米颗粒核心和与闪烁体发射波长相匹配的光敏药物。
在X射线照射下,纳米粒子闪烁体起到换能器的作用,将X射线光子转换为可见光
光光子。可见光反过来通过光敏药物激活附近的药物,产生一种细胞毒
被称为单线态氧的物种。由于X射线的良好透过性,X-PDT可以从深部激活
纸巾。此外,还发现X-PDT本质上是PDT和放射治疗的结合。这导致了
协同治疗结果,使X-PDT能够在低辐射剂量下有效地杀死癌细胞,即使在
对放射治疗无效的癌细胞。这些特点使X-PDT成为一种吸引人的治疗方法
方法论。
本项目将利用X-PDT治疗非小细胞肺癌(NSCLC),这是一项具有挑战性或
对于传统的光动力疗法是不可能的。非小细胞肺癌占所有肺癌病例的85%,被诊断为
每年有18.7万人。放射治疗通常与化疗同时进行,是治疗乳腺癌的标准治疗方法。
大多数患者。然而,这种治疗可能会引起严重的副作用,如中性粒细胞减少症和
三级食管炎。一旦复发,治疗选择就有限了,因为辐射已经给了
最大耐受量。因此,迫切需要一种有效且毒性较低的非小细胞肺癌治疗方法。它
预计X-PDT可通过相对低剂量、最小剂量的外照射有效地杀伤非小细胞肺癌
附带损害。
这一项目的成功将是范式的转变,打破了传统的肤浅的渗透教条
并开启了许多新的可能性。X-PDT在临床翻译、补充或治疗方面具有巨大潜力
取代目前的治疗方案用于非小细胞肺癌的治疗。虽然目前的研究重点是非小细胞肺癌,但
方法学可以很容易地扩展到其他类型的癌症的治疗,例如头颈癌,
乳腺癌和前列腺癌。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Jin Xie其他文献
Jin Xie的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Jin Xie', 18)}}的其他基金
Nanoscintillator-based X-ray sensitizers to enable efficient NSCLC treatment with X-ray irradiation
基于纳米闪烁体的 X 射线敏化剂可通过 X 射线照射实现有效的 NSCLC 治疗
- 批准号:
9899249 - 财政年份:2017
- 资助金额:
$ 49.23万 - 项目类别:
Nanoplatform-based combinational therapy against breast cancer
基于纳米平台的乳腺癌联合疗法
- 批准号:
8545104 - 财政年份:2010
- 资助金额:
$ 49.23万 - 项目类别:
Nanoplatform-based combinational therapy against breast cancer
基于纳米平台的乳腺癌联合疗法
- 批准号:
8335496 - 财政年份:2010
- 资助金额:
$ 49.23万 - 项目类别:
Nanoplatform-based combinational therapy against breast cancer
基于纳米平台的乳腺癌联合疗法
- 批准号:
8333479 - 财政年份:2010
- 资助金额:
$ 49.23万 - 项目类别:
相似海外基金
Unraveling Adverse Effects of Checkpoint Inhibitors Using iPSC-derived Cardiac Organoids
使用 iPSC 衍生的心脏类器官揭示检查点抑制剂的副作用
- 批准号:
10591918 - 财政年份:2023
- 资助金额:
$ 49.23万 - 项目类别:
Optimization of mRNA-LNP vaccine for attenuating adverse effects and analysis of mechanism behind adverse effects
mRNA-LNP疫苗减轻不良反应的优化及不良反应机制分析
- 批准号:
23K15383 - 财政年份:2023
- 资助金额:
$ 49.23万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of adverse effects of combined exposure to low-dose chemicals in the living environment on allergic diseases and attempts to reduce allergy
阐明生活环境中低剂量化学品联合暴露对过敏性疾病的不良影响并尝试减少过敏
- 批准号:
23H03556 - 财政年份:2023
- 资助金额:
$ 49.23万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Green tea-based nano-enhancer as an adjuvant for amplified efficacy and reduced adverse effects in anti-angiogenic drug treatments
基于绿茶的纳米增强剂作为抗血管生成药物治疗中增强疗效并减少不良反应的佐剂
- 批准号:
23K17212 - 财政年份:2023
- 资助金额:
$ 49.23万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Effects of Tobacco Heating System on the male reproductive function and towards to the reduce of the adverse effects.
烟草加热系统对男性生殖功能的影响以及减少不利影响。
- 批准号:
22H03519 - 财政年份:2022
- 资助金额:
$ 49.23万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Mitigating the Adverse Effects of Ultrafines in Pressure Filtration of Oil Sands Tailings
减轻油砂尾矿压力过滤中超细粉的不利影响
- 批准号:
563657-2021 - 财政年份:2022
- 资助金额:
$ 49.23万 - 项目类别:
Alliance Grants
1/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
1/4-破译ECT结果和不良反应的机制(DECODE)
- 批准号:
10521849 - 财政年份:2022
- 资助金额:
$ 49.23万 - 项目类别:
4/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
4/4-破译ECT结果和不良反应的机制(DECODE)
- 批准号:
10671022 - 财政年份:2022
- 资助金额:
$ 49.23万 - 项目类别:
2/4 Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
2/4 ECT 结果和不良反应的破译机制(DECODE)
- 批准号:
10670918 - 财政年份:2022
- 资助金额:
$ 49.23万 - 项目类别:
Adverse Effects of Using Laser Diagnostics in High-Speed Compressible Flows
在高速可压缩流中使用激光诊断的不利影响
- 批准号:
RGPIN-2018-04753 - 财政年份:2022
- 资助金额:
$ 49.23万 - 项目类别:
Discovery Grants Program - Individual